Syndax Pharmaceuticals (FRA:1T3) FCF Yield %: -15.03 (As of Jul. 02, 2026)


FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
25 GF Score
Price €18.96
! 7 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals FCF Yield %?

Syndax Pharmaceuticals FRA:1T3 -0.47% 25 FCF Yield % is -15.03 as of Jul. 02, 2026. GuruFocus rates FRA:1T3 with a GF Score™ of 25/100. The stock has 7 warning signs investors should review. Among 1,414 Biotechnology companies, Syndax Pharmaceuticals ranks worse than 59.83% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Syndax Pharmaceuticals's Trailing 12-Month Free Cash Flow is €-239.1 Mil, and Market Cap is €1,625.1 Mil. Therefore, Syndax Pharmaceuticals's FCF Yield % for today is -15.03%.

The historical rank and industry rank for Syndax Pharmaceuticals's FCF Yield % or its related term are showing as below:

FRA:1T3' s FCF Yield % Range Over the Past 10 Years
Min: -71.79   Med: -14.79   Max: 3.27
Current: -15.03


During the past 13 years, the highest FCF Yield % of Syndax Pharmaceuticals was 3.27%. The lowest was -71.79%. And the median was -14.79%.

FRA:1T3's FCF Yield % is ranked worse than
59.83% of 1414 companies
in the Biotechnology industry
Industry Median: -9.46 vs FRA:1T3: -15.03

Syndax Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was -77.62%.


Syndax Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Syndax Pharmaceuticals FCF Yield % Related Terms


Syndax Pharmaceuticals FCF Yield % Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals FCF Yield % Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.55 -8.20 -9.09 -25.74 -25.46

Syndax Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.68 -46.86 -21.44 -21.90 -10.04

FRA:1T3 vs IOVA, GLUE, TYRA: FCF Yield % Comparison

For the Biotechnology subindustry, Syndax Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's FCF Yield % falls into.


FRA:1T3
25GF Score
Syndax Pharmaceuticals Inc FRA:1T3
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Syndax Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-275.985 / 1083.8344
=-25.46%

Syndax Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-43.548 * 4 / 1735.4624
=-10.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -15.03 mean?
Syndax Pharmaceuticals (FRA:1T3) has a FCF Yield % of -15.03 as of Jul. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Syndax Pharmaceuticals and its competitors. According to the industry distribution chart, Syndax Pharmaceuticals ranks #846 out of 1414 companies in the Biotechnology industry, placing it in the top 59.8%.
Is Syndax Pharmaceuticals' FCF Yield % too high?
Syndax Pharmaceuticals' current FCF Yield % is -15.03. Based on the distribution chart, Syndax Pharmaceuticals ranks #846 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' FCF Yield % compare to IOVA and GLUE?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #846 out of 1414 companies for FCF Yield %. This places Syndax Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current FCF Yield % is -15.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current FCF Yield % of -15.03. The current FCF Yield % is -15.03. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current FCF Yield % is -15.03 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score

Get the complete analysis for FRA:1T3

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.96
Price